Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...
Humanwell Healthcare Receives NMPA Approval for Compound Sodium Lactate Ringer’s Injection
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products...
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...
MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector
US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...
Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume
The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...
AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...
Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...
Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...
Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance
US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...
Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...
Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...
Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...
CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...
Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...
Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase
US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...
HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments
Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with...